Clinical Findings Documenting Cellular and Molecular Abnormalities of Glia in Depressive Disorders
- 1Neurobiology of Stress Research Group, Szentágothai Research Center, University of Pécs, Pécs, Hungary
- 2Department of Laboratory Medicine, University of Pécs, Medical School, Pécs, Hungary
- 3Department of Neurosurgery, University of Pécs, Medical School, Pécs, Hungary
- 4MTA-PTE, Clinical Neuroscience MR Research Group, Pécs, Hungary
- 5Pécs Diagnostic Centre, Pécs, Hungary
Depressive disorders are complex, multifactorial mental disorders with unknown neurobiology. Numerous theories aim to explain the pathophysiology. According to the “gliocentric theory”, glial abnormalities are responsible for the development of the disease. The aim of this review article is to summarize the rapidly growing number of cellular and molecular evidences indicating disturbed glial functioning in depressive disorders. We focus here exclusively on the clinical studies and present the in vivo neuroimaging findings together with the postmortem molecular and histopathological data. Postmortem studies demonstrate glial cell loss while the in vivo imaging data reveal disturbed glial functioning and altered white matter microstructure. Molecular studies report on altered gene expression of glial specific genes. In sum, the clinical findings provide ample evidences on glial pathology and demonstrate that all major glial cell types are affected. However, we still lack convincing theories explaining how the glial abnormalities develop and how exactly contribute to the emotional and cognitive disturbances. Abnormal astrocytic functioning may lead to disturbed metabolism affecting ion homeostasis and glutamate clearance, which in turn, affect synaptic communication. Abnormal oligodendrocyte functioning may disrupt the connectivity of neuronal networks, while microglial activation indicates neuroinflammatory processes. These cellular changes may relate to each other or they may indicate different endophenotypes. A theory has been put forward that the stress-induced inflammation—mediated by microglial activation—triggers a cascade of events leading to damaged astrocytes and oligodendroglia and consequently to their dysfunctions. The clinical data support the “gliocentric” theory, but future research should clarify whether these glial changes are truly the cause or simply the consequences of this devastating disorder.
Depressive disorders are a leading cause of disease burden globally (Ferrari et al., 20131). There are effective therapeutic interventions available, but the currently existing antidepressant medications are far from being optimal as they have numerous side effects and large percentage of the patients do not respond to them (e.g., Anderson, 2000; Montgomery et al., 2002; Millan, 2006; Rush et al., 2006; Cipriani et al., 2009). There is an urgent need for new, faster acting, more effective drugs. Understanding the pathophysiology could help us in the development of novel therapies.
Despite extensive investigations, the exact neurobiological processes leading to depression are not fully understood. According to our present comprehension depressive disorders develop as a result of interactions between genetic predispositions and environmental factors (see e.g., Halldorsdottir and Binder, 2017; Bleys et al., 2018; Zhao et al., 2018; but also Culverhouse et al., 2018). The most widely accepted classic theory regarding the underlying neuropathology is the monoamine imbalance hypothesis, which emphasizes the role of disturbed monoamine neurotransmission in the synaptic cleft (Meyer et al., 2006; Belmaker and Agam, 2008; Nikolaus et al., 2009). However, it has become evident that this monoamine theory of depression does not explain the wide spectrum of macroscopic and microscopic structural changes that have been repeatedly documented in the brains of depressed patients. Currently, there are at least a dozen of theories aiming to explain the pathophysiology and here we focus on the “gliocentric hypothesis” of depression. The aim of this review is to summarize the clinical findings documenting glial changes in mood disorders based on the in vivo neuroimaging and the postmortem molecular and quantitative histopathological data.
Traditionally, the term “mood disorders” included both the bipolar and the depressive disorders, but now, in the DSM-5 there are separate sections for the Bipolar Disorders (BDs) and for the Depressive Disorders. All these terms mean larger categories and include several disorders. Here, we occasionally need to use the old terminology, since the majority of the studies have been done before the DSM-5. Most of the clinical studies discussed here involved patients either with Major Depressive Disorder (MDD) or with BD.
Cellular Evidences for Glial Pathology
Postmortem Quantitative Histopathological Data
We start with the postmortem histopathological findings since historically these were the first to reveal glial alterations in the brains of depressed individuals. The first reports were published in the late 90s. At that time, the scientific community was excited by the results of the in vivo imaging studies documenting reduced activity and volume shrinkage in the prefrontal cortex (PFC) of depressed patients (Drevets et al., 1997). To understand the cellular pathology behind these functional and morphological changes researchers started to carry out quantitative light microscopic analyses on postmortem PFC samples from depressed patients. The investigators expected to find changes in neuron numbers and morphology, but it turned out that in most cases the morphometric alterations affected glial cells. The first report found markedly reduced glial numbers in the ventromedial PFC (subgenual Brodmann’s area 24) in the brains of patients with MDD and BD (Öngür et al., 1998). The most prominent reduction of glial cell numbers was observed in subjects with familial MDD (24%) or BD (41%; Öngür et al., 1998). In their study, Öngür et al. (1998) used schizophrenic brains as psychiatric controls which had normal neuronal and glial cell numbers. These findings evoked great interest and were followed by numerous confirmatory reports. Reduced density of glial cells was found in the dorsolateral PFC (Cotter et al., 2002) and in the rostral and caudal orbitofrontal cortex of depressed patients (Rajkowska et al., 1999). A follow-up study by Rajkowska et al. (2001) revealed similarly reduced glial density in the dorsolateral PFC of patients with BD. More recent studies confirmed the findings on decreased density of glial cells in the anterior cingulate cortex (ACC; Brodmann area 24b; Gittins and Harrison, 2011). The histological studies on glial cell loss are supported by the recent molecular findings on altered microRNA (miRNA) levels in the brains of BD patients. For example Choi et al. (2017) extracted extracellular vesicles from the PFC (Brodmann area 24) and found increased levels of miR-149 exclusively in glial cells. Since miR-149 can inhibit glial cell proliferation thus, increased miR-149 expression might contribute to the glial cell number reduction.
The first studies focused on the different subareas of the PFC, but later the investigators analyzed other limbic areas and found similar glial changes. In the amygdala, reduced glial density and glia/neuron ratio was found in MDD (Bowley et al., 2002). This reduction was more pronounced in the left hemisphere and no change was found in neuron numbers (Bowley et al., 2002). In BD subjects, who did not receive mood stabilizer medication, significantly reduced glial cell numbers were found, in contrast to the cases who were treated with lithium or valproate (Bowley et al., 2002). This later finding indicated that medication may affect glial cell numbers (see also “Experimental Evidences That Psychotropic Medication Can Affect Glial Cell Numbers” section).
In the hippocampus, the first detailed human postmortem study found no evidence for neuronal abnormality, but the packing density of glial cells was significantly increased in all hippocampal subfields of patients with MDD (Stockmeier et al., 2004). A follow up study by the same group could not find any difference in the total cell numbers of neurons and glia in any hippocampal subarea (Cobb et al., 2013), but later they reported on reduced density of astrocytes in the hilus (Cobb et al., 2016).
Obviously, these postmortem histopathological studies have their limitations (the problem of tissue preservation and finding adequate controls), thus, some scientists question their scientific soundness. But in fact most of the in vivo neuroimaging and preclinical experimental data support the postmortem findings. Ideally, one should carry out longitudinal studies on well-characterized patients with repeated neuroimaging investigations and in the end one should do postmortem analysis on the brains of the same subjects (Stockmeier and Rajkowska, 2004). However, so far such studies are not available.
Finally, we should note here that there are also negative findings on glial cell numbers in the literature (e.g., Damadzic et al., 2001; Cotter et al., 2005; Khundakar et al., 2011; Rubinow et al., 2016).
Postmortem Evidences for Astrocytic Abnormalities
Most of the above mentioned histopathological studies used Nissl stained brain samples which is not suitable for the identification of the different glial subtypes. The later studies used immunohistochemistry which enabled us to specify which type of glial cells are affected by the disease. Numerous studies found evidences for altered number or disrupted integrity of astrocytes in depressed patients. For example, Miguel-Hidalgo et al. (2000) studied glial fibrillary acidic protein (GFAP)-immunoreactive astrocytes in the dorsolateral PFC of MDD subjects, and found a significant reduction of areal fraction and packing density of GFAP-positive cell bodies, but only in younger (30–45 years old) patients, whereas in older subjects (46–86 years old) these glial parameters tended to be greater compared to the corresponding controls. In line with these data, reduced GFAP protein levels were reported by a western blot study analyzing PFC samples from patients with MDD (Si et al., 2004). A more recent study investigated the coverage of blood vessels by aquaporin (AQ)-4-immunoreactive astrocytes in the PFC of MDD patients and found 50% reduction in the orbitofrontal gray matter (Rajkowska et al., 2013). In the same study, the coverage of blood vessels by GFAP-positive endfeet processes did not differ between the groups (Rajkowska et al., 2013). Others reported on reduced GFAP immunoautoradiography in the white matter of the ACC (Brodmann area 24b; Gittins and Harrison, 2011). Yet another study which did a very detailed analysis on the morphology of Golgi-impregnated astrocytes found that the fibrous astrocytes (in the white matter) had significantly larger cell bodies, as well as longer, more ramified processes in depressed suicide victims in the ACC (Brodmann area 24; Torres-Platas et al., 2011). Another study found decreased area fraction and increased cell clustering of GFAP expressing astrocytes in the postmortem white matter adjacent to the dorsolateral PFC (Brodmann area 9) of BD patients (Hercher et al., 2014).
Alterations of astrocytes have also been reported in the hippocampi of depressed patients. A study focusing on the density of GFAP-positive astrocytes found reduced density of astrocytes in the dentate hilus, but not in other hippocampal subareas (Cobb et al., 2016). Furthermore, this decrease was present only in those depressed patients who were not taking antidepressant medications, but not in subjects who were medicated (Cobb et al., 2016). Another group found reduced density of S100B-immunopositive astrocytes in the hippocampal CA1 pyramidal cell layer of MDD and BD patients (Gos et al., 2013). Reduced density of GFAP-immunoreactive astrocytes was also found in the amygdala of depressed patients (Altshuler et al., 2010) and downregulation of GFAP mRNA and protein expression was reported in the thalamus and caudate nucleus of depressed suicides (Torres-Platas et al., 2016).
Since it is increasingly acknowledged that astrocytes play a number of vital roles in the CNS (e.g., maintaining synaptic homeostasis, modulating glutamate metabolism, participating in signaling between neurons and glia, neurotrophic support, etc.) thus, a theory had been put forward proposing that depressive disorders are the consequence of the disturbed astrocytic functioning (see e.g., Wang et al., 2017). The summary of astrocytic abnormalities in depressed patients is shown on Table 1.
Postmortem Evidences for Oligodendrocyte Abnormalities
Similarly to astrocytes, deficit of oligodendrocytes has been repeatedly documented in the PFC of MDD and BD patients. The first report was an electron microscopic study demonstrating ultrastructural evidences for apoptosis and necrosis of oligodendroglial cells in the prefrontal area 10 in BD (Uranova et al., 2001). In a follow-up study, the same group studied the numerical density of oligodendroglial cells in layer VI of the Brodmann area 9 in BD, MDD and healthy controls. They found a significantly reduced density of oligodendrocytes in BP and MDD patients (Uranova et al., 2004). Later, the same group demonstrated a prominent reduction in the number of perineuronal oligodendrocytes in layer III of the Brodmann area 9 in BP and MDD (Vostrikov et al., 2007). These findings are supported by more recent studies, using different cell counting techniques, but also reporting on reduced density of oligodendrocytes in the PFC Brodmann area 10 (Hayashi et al., 2011). Finally, a recent study found significantly decreased soma size of 2′,3′-Cyclic-nucleotide 3′-phosphodiesterase enzyme (CNPase)-immunoreactive oligodendrocytes in the ventral PFC white matter of MDD patients (Rajkowska et al., 2015). Complementing these quantitative findings, another study found reduced immunoreactivity of the myelin basic protein (an oligodendrocyte marker) in the anterior frontal cortex of depressed individuals who died by suicide (Honer et al., 1999). Another group found reduced density of S100B-immunopositive oligodendrocytes in the left hippocampal alveus of BD patients (Gos et al., 2013). More recently, a study found increased oligodendrocyte density in the postmortem white matter adjacent to the dorsolateral PFC (Brodmann area 9) of BD patients (Hercher et al., 2014). One should add here that there is a recent study which investigated the axonal myelin sheath in the genu of the corpus callosum and found that the myelin thickness was actually greater in MDD (Williams et al., 2015).
These neuroanatomical findings on oligodendroglial changes have been extended by a study which compared microarray metadata with the cytoarchitectural data. Correlation analysis between the genome-wide gene expression levels and cytoarchitectural traits revealed that 818 genes were significantly correlated with the decrease in the number of perineuronal oligodendrocytes in psychiatric subjects (Kim and Webster, 2010).
Based on these findings, it has been proposed that impaired oligodendrocyte functioning alters neuronal circuitry and by that leads to disrupted mood regulation in psychiatric disorders. For details of this concept see e.g., Edgar and Sibille (2012). The summary of oligodendrocyte abnormalities in depressed patients is shown on Table 2.
Postmortem Evidences for Activated Microglia
Microglial cells are the resident immune cells of the brain. Large body of evidence support the notion that neuroinflammation contributes to the pathophysiology of depression (Rosenblat et al., 2014) and numerous scientists proposed that microglial cells play a key role in the pathogenesis of depressive disorders (Brites and Fernandes, 2015; Yirmiya et al., 2015; Singhal and Baune, 2017). But in fact, so far only a handful of postmortem studies focused on microglial cells in the brains of depressed individuals. The first study to do that was a report on the presence of activated microglia in the hippocampal CA1 area using immunohistochemical staining with the HLA-DR antibody (Bayer et al., 1999). Later Steiner et al. (2008, 2011), provided further important evidences on microglial activation in various psychiatric illnesses. The summary of microglial changes in depressed patients is shown on Table 3.
A more recent study analyzed Iba-1-immunoreactive microglial cells in the white matter of the dorsal ACC and found that the ratio of primed over ramified (“resting”) microglia was significantly increased in depressed suicides (Torres-Platas et al., 2014). In the same study, the proportion of blood vessels surrounded by macrophages was more than twice higher in depressed suicides than in controls (Torres-Platas et al., 2014). Consistent with these observations, gene expression analysis of Iba-1 and monocyte chemoattractant protein-1 (MCP-1; a chemokine involved in the recruitment of circulating monocytes), was significantly up-regulated in depressed suicides (Torres-Platas et al., 2014). Another study found greater density of Iba-1-immunoreactive cells in contact with blood vessels in the dorsal prefrontal white matter of suicide victims (Schnieder et al., 2014).
Experimental Evidences That Psychotropic Medication Can Affect Glial Cell Numbers
Ideally, a postmortem study investigating cellular changes in the brains of depressed individuals should use tissue samples from medication free patients. However, nowadays it is very difficult to get such samples, because most patients with depressive disorder or BD receive long-term treatment with various drugs. Thus, when a human postmortem study reports on altered cell numbers in specific brain areas, the next question to be answered: is this change due to the illness, or is this the result of the medication? To answer this question, several groups examined neuronal and glial cell numbers in the brains of experimental animals subjected to antidepressant, antipsychotic or mood stabilizer treatment. For example, a study treated macaque monkeys with antipsychotic drugs such as haloperidol and olanzapine (at doses producing plasma levels in the therapeutic range) and found that glial cell numbers were significantly reduced in the parietal cortex (Konopaske et al., 2007). In a follow up study, the same group reported that these glial changes affected mainly the astrocytes, since a significant loss of astrocytes were found in addition to a non-significant reduction in oligodendrocyte cell number in the antipsychotic-treated monkeys (Konopaske et al., 2008). Haloperidol and olanzapine had equivalent glia-reducing effect (Konopaske et al., 2008). A more recent study investigated the effect of lithium treatment on glial cell numbers in the PFC and dentate gyrus of mice (Rajkowska et al., 2016). Lithium is a widely used mood stabilizer and many patients with BD receive long-term lithium treatment. This experimental study found that lithium treatment can increase the total numbers of neurons and glia in the dentate gyrus and also the density of astrocytes in the PFC of mice (Rajkowska et al., 2016). Besides lithium, valproic acid is a classic choice to treat manic or mixed episodes of BD. There is increasing evidence that chronic valproic acid treatment can influence myelination and network connectivity (Rosenzweig et al., 2012). We also did an experimental study to examine the effect of an antidepressant drug (fluoxetine, a selective serotonin reuptake inhibitor) on astrocytes in an animal model for depression. We found that fluoxetine could reverse the chronic stress-induced loss of astrocytes in the hippocampus of the animals (Czéh et al., 2006). Furthermore, treatment with psychoactive agents not only affects glial cell numbers, but also influences cellular morphology. It has been shown that fluoxetine treatment can increase the plasticity of astrocytic end-feet processes and enhance their numbers (Di Benedetto et al., 2016). Similarly to that, a study using a non-human primate model of self-injurious behavior reported that naltrexone treatment can reverse astrocyte atrophy associated with self-harm (Lee et al., 2015).
Adult hippocampal neurogenesis in the dentate gyrus is a cellular process that has been linked to the pathophysiology of depressive disorders (see e.g., Miller and Hen, 2015). Numerous studies document that antidepressant treatments can stimulate adult hippocampal neurogenesis and parallel to this several studies investigated the effect of antidepressant treatment on gliogenesis in the CNS of experimental animals. Several reports document increased gliogenesis in the PFC of adult rats after antidepressant or antipsychotic treatment (Kodama et al., 2004; Czéh et al., 2007). Likewise, electroconvulsive treatment stimulates gliogenesis in the PFC (Madsen et al., 2005; Öngür et al., 2007), hippocampus (Wennström et al., 2006), and amygdala (Wennström et al., 2004). These treatments stimulated the proliferation of NG2-positive glial cells. In contrast to the stimulating effect of antidepressants, lithium treatment appears to inhibit the proliferation of NG2 cells in the hippocampal dentate hilus, amygdala and corpus callosum (Orre et al., 2009).
In summary, experimental data indicate that drugs, characteristically used to treat MDD and BD, can all affect glial cell numbers, cellular morphology, gliogenesis and probably also myelination. This should be kept in mind when we interpret the postmortem clinical findings, because most brain samples originate from individuals who received long-term medications during the course of their illness.
In Vivo Imaging Studies
In vivo neuroimaging is a valuable tool to examine glial alterations in depressive disorders. The volumetric magnetic resonance imaging (MRI) studies reveal reduced volumes of specific brain areas in depression (e.g., van Tol et al., 2010; Grieve et al., 2013). These volume changes are likely to be the gross consequence of the glial and/or neuronal cell loss. There are numerous novel in vivo imaging methods which can be employed to examine brain structure and function. These methods include the diffusion tensor imaging (DTI), functional magnetic resonance imaging (fMRI), proton magnetic resonance spectroscopy (1H-MRS) and positron emission tomography (PET) imaging. Here, we summarize the in vivo clinical findings documenting glial abnormalities in patients with depressive disorders.
Astrocytes carry out a large variety of important cellular functions for the neuronal microenvironment such as the regulation of glucose metabolism, neurotransmitter uptake (particularly glutamate, the major excitatory neurotransmitter), regulation of synaptic development and maturation and maintenance of the blood brain barrier (Kettenmann and Ransom, 2005). In PET imaging, the uptake of the radioactive 18F-deoxyglucose by astrocytes is associated with neuronal activity (Magistretti and Pellerin, 1999). A well replicated finding in PET studies is the reduced glucose metabolism in the PFC of MDD patients (Baxter et al., 1989). Typically this is more pronounced in depressed periods and slightly normalized in the remission phase (Martinot et al., 1990; Drevets et al., 2002a). Mounting evidence supports the existence of abnormal glucose metabolism in other brain regions including the amygdala (Abercrombie et al., 1998; Drevets et al., 2002b), thalamus (Su et al., 2014), and the lateral temporal and parietal cortex (Drevets et al., 1992), however these later ones are less consistent.
Numerous 1H-MRS studies examined glutamate, glutamine and Glx (a composite measure of glutamate and glutamine) levels in the context of mood disorders (reviewed by Yüksel and Öngür, 2010). These studies find a highly consistent pattern of Glx level reductions in MDD and elevations in BP (Yüksel and Öngür, 2010). Furthermore, the available data suggest that in depressive states reduced glutamine/glutamate ratio can be detected, whereas in mania an elevated glutamine/glutamate ratio is present (Yüksel and Öngür, 2010; Luykx et al., 2012; Arnone et al., 2015). These metabolic changes are likely to be the consequences of the altered astrocytic functioning. A recent meta-analysis based on 17 studies using 1H-MRS revealed an exclusive reduction in Glx levels in the PFC of MDD patients (Arnone et al., 2015). The same meta-analysis reported that there was no change in glutamate levels and other metabolite levels were also not altered (Arnone et al., 2015). Other investigation found normal or slightly elevated glutamate and glutamine levels in remitted MDD (Bhagwagar et al., 2007), which suggests that Glx may be restored or compensated after successful treatment (Michael et al., 2003; Pfleiderer et al., 2003).
Several PET studies investigated tracer binding to the metabotropic glutamate receptor 5 (mGluR5) which is a key component of the glutamatergic system and expressed by neurons and astrocytes (Biber et al., 1999). A study by Deschwanden et al. (2011) used the radiotracer [11C]ABP688 and found reduced mGluR5 binding in the PFC, cingulate cortex, insula, thalamus, and hippocampus of MDD patients. However, more recently a study using a different radiotracer, [18F]FPEB, could not confirm this finding (Abdallah et al., 2017).
In case of BD patients, the picture is less ambiguous, because numerous studies consistently report on increased Glx and glutamate levels in several brain areas (Frye et al., 2007; Gigante et al., 2012; Soeiro-de-Souza et al., 2015). A study which involved both melancholic and non-melancholic subtypes of BD found that Glx and glutamate concentrations were significantly higher in the non-melancholic subtype (Frye et al., 2007). Furthermore, patients who responded to lamotrigine treatment had reduced glutamine concentration (Frye et al., 2007). Notably, up to 80% of glutamate is compartmentalized in neurons while glutamine is synthetized mainly in astrocytes (Maddock and Buonocore, 2012; Ramadan et al., 2013), hence, both astrocytic and neuronal dysfunction can lead to changes in glutamine and glutamate levels (see also “Molecular Evidences From Clinical Studies: Astrocytic Abnormalities” section).
Lactate is an important metabolite in the brain with unknown function. Astrocytes contribute to lactate metabolism in the brain (Mächler et al., 2016; Mason, 2017). Furthermore, lactate can be processed by mitochondrial oxidative metabolism (Pellerin et al., 2007) and recent theories suggest mitochondrial dysfunction in depressive disorders (Manji et al., 2012; Klinedinst and Regenold, 2015). Supporting this concept, elevated gray matter lactate was found in the cingulate gyrus of BD patients (Dager et al., 2004) and in the pregenual ACC of patients with MDD (Ernst et al., 2017).
It is well known, that astrocytic glycolysis and oxidative phosphorylation results in a clear signal change in fMRI measurements (Rossi, 2006; Attwell et al., 2010). Numerous studies document fMRI alterations in fronto-cortical areas of MDD patients (e.g., Grimm et al., 2008; Mulders et al., 2015; Davey et al., 2017), but it is not known which cell type is responsible for the alterations. In the PFC, the coverage of blood vessels by astrocytic endfeets is markedly reduced in patients with MDD suggesting that the blood flow and glucose uptake by astrocytes might be impaired (Rajkowska et al., 2013). This neuroanatomical alteration could consequently result in fMRI signal change. Plenty of evidences document that antidepressant treatment (e.g., fluoxetine, paroxetine) positively affect astrocytic function by regulating glucose metabolism (Kennedy et al., 2001; Allaman et al., 2011; Czéh and Di Benedetto, 2013) and consequently cause fMRI signal change (Harris and Reynell, 2017). Interestingly, antidepressant treatment can affect the BOLD response to positive and negative emotional stimuli differently especially in frontal brain areas (Ma, 2015).
Oligodendroglia provides support and insulation to axons by creating the myelin sheath. Consequently, oligodendrocyte pathology can cause abnormal development, demyelination or reduction of myelinated axons. Oligodendrocyte abnormalities can be investigated in vivo using DTI. DTI was specifically developed to investigate the integrity of white matter, where axons and myelin sheaths form longitudinal axes leading to greater water diffusion along the tracts and restricted molecular displacement perpendicularly. Fractional anisotropy (FA) measures the magnitude of directionally varying diffusion restriction effect, while mean diffusivity (MD) represents the average diffusion coefficient in all direction.
A significant number of DTI studies found robust FA reductions in the corpus callosum and in several frontal and temporal regions (e.g., Alexopoulos et al., 2002; Taylor et al., 2004; Bae et al., 2006; Ma et al., 2007; de Diego-Adeliño et al., 2014; Yamada et al., 2015; Jiang et al., 2017) indicating white matter microstructural abnormalities in depressed patients. Later studies found similar microstructural abnormalities in the anterior callosal fibers connecting bilateral frontal cortices in patients with MDD (Yamada et al., 2015; Matsuoka et al., 2017). Another study reported on significant FA deficits only in the right parietal white matter in depressed patients as well as white matter changes of specific thalamic tracts (Osoba et al., 2013).
DTI studies document abnormal white matter microstructure in BD patients as well. Untreated bipolar patients with first episode psychosis showed lower FA in several white matter tracts such as the cingulum, internal capsule, posterior corpus callosum, tapetum and occipital white matter (Lu et al., 2011). At the same time, BD patients have greater MD in the cingulum, corpus callosum, corona radiata, internal capsule, tapetum and occipital white matter including posterior thalamic radiation, inferior longitudinal fasciculus/inferior fronto-occipital fasciculus (Lu et al., 2011). Numerous follow up studies confirmed these data (Lu et al., 2012; Emsell et al., 2013; Sprooten et al., 2016; Ji et al., 2017). Similar, but more subtle white matter microstructural changes were detected in unaffected siblings as well (Sprooten et al., 2013, 2016). A recent study reported that these alterations are less pronounced in euthymic BD patients and that lithium treatment can counteract the white matter microstructural abnormalities (Haarman et al., 2016b).
There are other imaging methods to quantitatively evaluate myelin related white matter alterations. Magnetization transfer imaging is based on the interaction of unbound protons and protons bound to macromolecules. Myelin bound protons associated with protein and lipid macromolecules are not measurable by conventional MRI. During magnetization transfer imaging an off-resonance pulse is applied to partially saturate the macromolecular pool and produce contrast between tissues. This suppresses the water signal which can be measured by magnetization transfer ratio (MTR) and associated with macromolecular concentration. Hence, increased MTR in the white matter indicates remyelination, whereas decreased MTR indicates demyelination (Chen et al., 2008). Besides the gray matter MTR changes (Chen et al., 2015; Jia et al., 2017), the white matter also depicts alterations in depressive disorders. Reduced myelin integrity was suggested in late-life depression where decreased MTR was found in multiple left hemisphere frontostriatal, limbic areas, occipital white matter and in the genu and splenium of the corpus callosum (Kumar et al., 2004; Gunning-Dixon et al., 2008). Subtle abnormalities were presented in the anterior cingulate and subgyral white matter in patients with BD reflecting myelin changes and/or reduced axon density (Bruno et al., 2004).
Growing number of evidences indicate that cerebral white matter lesions contribute to the pathophysiology of depression. Recent studies demonstrate that the volume of periventricular and deep white matter lesions are differently associated with depressive symptoms (Tully et al., 2017). These are also present in suicidal behavior of MDD and BD patients (Pompili et al., 2008; Grangeon et al., 2010). Despite their similar appearance, some authors suggest that lesions in different brain areas may have distinct origin and functional consequences. Accordingly, periventricular white matter lesions have been found to have lower MTR than the ones in deep white matter, suggesting different underlying pathology and mechanisms (Spilt et al., 2006). It is argued that these white matter lesions should result in impaired connectivity of different brain regions. Lower white matter microstructural integrity (measured by DTI) and altered brain function (measured by fMRI) were found in white matter lesions (Smagula and Aizenstein, 2016). Others reported more widespread changes in white matter connectivity and lesions in BD compared to MDD (Cardoso de Almeida and Phillips, 2013). Overall, these data suggest that white matter lesions contribute to the development of depressive disorders.
1H-MRS is another in vivo method to assess cellular integrity and functioning in the brains of psychiatric patients (see e.g., Yildiz-Yesiloglu and Ankerst, 2006; Caverzasi et al., 2012). With this method one can measure the concentration of various brain metabolites, typically, N-acetylaspartate (NAA), Choline (Cho), myo-inositol (mI), Glutamate (Glu)/Glutamine (Gln) and Creatine (Cr). NAA plays a role in various cellular functions such as osmoregulation, energy homeostasis and possibly also in myelin production (Moffett et al., 2007). NAA levels in the CNS provide information on the functioning of both neurons and oligodendrocytes. For example, significantly lower NAA to Cr ratio was found in the dorsolateral prefrontal white matter in first episode treatment-naive patients with MDD (Wang et al., 2012). Similarly, reduced NAA/Cr ratio was found in patients with BD in the medial prefrontal white matter (Zhong et al., 2014). These results indicate that, in vivo NAA changes do not reflect neuronal alterations alone, but also glial dysfunctions, both in MDD and BD.
PET is a well-established method to detect ongoing demyelination and remyelination processes in vivo (Stankoff et al., 2006, 2011; Wang et al., 2009; Wu et al., 2010; Tiwari et al., 2016), but to our best of knowledge so far no one investigated myelin related alterations in depressive disorders using PET imaging.
Neuroinflammatory processes have been repeatedly implicated in the pathophysiology of depression. As noted earlier, microglia is a key component of the immune system and seems to contribute to the pathophysiology of depression (Eyre and Baune, 2012). Activated microglia and neuroinflammation can be studied with PET imaging, using dedicated radiopharmaceuticals targeting the translocator protein-18 kDa (TSPO). In MDD, TSPO-specific VT (an index of TSPO density) was significantly increased by the magnitude of 30% in the PFC, ACC and insula using [18F] FEPPA radiopharmaceutical (Setiawan et al., 2015). In euthymic BD, elevated TSPO binding was found by the [11C] PK-11195 ligand in the right hippocampus compared to healthy controls (Haarman et al., 2014). However, another study using [11C] PBR28 found no significant difference between mild-to-moderate MDD patients and controls across a range of gray matter regions (Hannestad et al., 2013). Interestingly, Holmes et al. (2018) found that TSPO availability (measured by [11C] PK-11195 radioligand) was higher in the ACC and insula of MDD patients with suicidal thoughts compared to patients without such intention. They also provided the first evidence that increased TSPO may be more associated with suicidality than the MDD diagnosis itself (Holmes et al., 2018). Although the applied methodology and the binding affinity patterns of TSPO PET ligands can be different across the studies, these findings are the most compeling evidences for ongoing neuroinflammation, and for microglial activation during depressive episodes.
It has been suggested that 1H-MRS can also detect activated microglia-induced metabolic changes associated with neuroinflammation in depressive states (Haroon and Miller, 2017). Inflammatory cytokines have been shown to influence glutamate metabolism in MDD, but in the literature one can find contradictory findings. The majority of studies have shown decreased Glx in the ACC, amygdala, hippocampus and in different subregions of the PFC (Yüksel and Öngür, 2010), while others reported increased glutamate in other brain areas (Sanacora et al., 2004). After various treatment protocols, including a serotonin reuptake inhibitor drug (citalopram, Taylor et al., 2008), electroconvulsive therapy (Zhang et al., 2013) and sleep deprivation (Murck et al., 2009) the concentration of Glx can normalize in the brains of MDD patients.
Studies involving BD patients have consistently reported increased Glx levels both in medication free and treated patients (Gigante et al., 2012). Furthermore, a recent study reported that neuronal integrity markers NAA and N-acetyl-aspartyl-glutamate correlated with microglia activation (measured by TSPO). Based on this, it was proposed that some microglia can induce apoptosis while others stimulate adult neurogenesis (Haarman et al., 2016a). Finally, we should emphasize that methodological heterogeneity of the 1H-MRS studies (e.g., absolute concentration or ratio measurement, sample size, field strength, voxel location and geometry, etc.) may account for the contradictory results (Yüksel and Öngür, 2010).
Several studies reported that therapeutic administration of IFN-alpha (e.g., to treat viral infections) can induce profound inflammatory response and interacts with serotonin metabolism and increases glutamate which all in turn can result in depressive mood (Raison et al., 2009; Haroon et al., 2014). INF-alpha administration was associated with increased activity in the dorsal ACC and linked to impaired cognitive performance (Capuron et al., 2005). A recent resting-state fMRI study demonstrated that increased plasma concentration of C-reactive protein (a marker for inflammation) was associated with decreased connectivity between the ventral striatum and ventromedial PFC, which in turn correlated with increased anhedonia (Felger et al., 2016). Another resting-state fMRI study which used large multisite sample showed that depression can be subdivided into four subgroups by dysfunctional connectivity patterns in limbic and frontostriatal networks and also predicted the responsiveness to transcranial magnetic stimulation therapy (Drysdale et al., 2017).
Molecular Evidences from Clinical Studies
There are numerous direct and indirect molecular evidences indicating altered astrocyte functioning in depressive disorders. Several studies reported an age-dependent reduction in the expression level of GFAP in the PFC of MDD patients (Miguel-Hidalgo et al., 2000; Si et al., 2004). Reduced expression of GFAP mRNA levels were found in the white matter of the ACC in bipolar patients (Webster et al., 2005). Reduced GFAP expression was found also in the locus coeruleus (Chandley et al., 2013) and in the cerebellum (Fatemi et al., 2004) of patients with MDD.
GFAP corresponds to GFAP—an intermediate filament protein—which has become the prototypical marker for immunohistochemical identification of astrocytes. The exact functional role of GFAP is unknown, but it has been suggested to play a role in astrocyte-neuron interactions and glial scar formation upon CNS injury (Sofroniew and Vinters, 2010) as well as in intracellular vesicle trafficking (Potokar et al., 2010).
Astrocytes are key cellular elements regulating glutamate concentrations both in the synaptic cleft and in the extracellular space (Haydon and Carmignoto, 2006). Numerous MRS studies reported on altered levels of glutamate-related metabolites in mood disorders (see “In Vivo Imaging Studies: Astrocytic Abnormalities” section). In line with this, a postmortem study reported reduced densities of glutamine synthetase expressing astrocytes in specific cortical gray matter areas in MDD (Bernstein et al., 2015). Glutamine synthetase catalyzes the ATP-dependent condensation of ammonia and glutamate to form glutamine, and by that plays a central role in glutamate and glutamine homoeostasis. In addition to this, several studies documented reduced expression of astrocyte specific glutamate transporter genes (EAAT1, EAAT2 or SLC1A2, SLC1A3) in the orbitofrontal cortex (Miguel-Hidalgo et al., 2010), dorsolateral PFC (Choudary et al., 2005; Zhao et al., 2016), hippocampus (Medina et al., 2013, 2016) and locus coeruleus (Bernard et al., 2011; Chandley et al., 2013) of patients with MDD. In sum, there are ample evidences from different sources that glutamate and glutamine metabolism is impaired in depressed patients as well as in manic episodes (Öngür et al., 2008), which suggests aberrant functioning of astroglial cells in depressed patients (Haroon et al., 2017). We should also cite here a recent preclinical study which demonstrated that blockade of the astrocytic glutamate transporter (GLT-1) in the central amygdala can induce anhedonia and anxiety in rats (John et al., 2015).
Other astrocytic functions are also disturbed in depressive disorders. For example altered expression of glial gap junction proteins have been reported, indicating changes in astrocyte-astrocyte communication. Downregulation of connexin 30 and 43 expressing genes were found in several brain areas (Nagy et al., 2017), and reduced gene expression of the gap junction protein (GJA1) was reported in the hippocampus (Medina et al., 2016).
Finally, there are evidences on reduced gene expression of potassium and water channels (KCNJ10, AQP4) in the hippocampus of depressed patients (Medina et al., 2016).
The first study to document changes in oligodendrocyte-specific genes in the brains of psychiatric patients was done by Tkachev et al. (2003). They used differential display PCR, quantitative PCR and microarray analysis which provided evidences on reduced oligodendrocyte-related and myelination-associated gene expression in the brains of patients who had schizophrenia and BD. Later, Aston et al. (2005) reported on altered gene expression in the temporal cortex of MDD patients, which suggested oligodendroglial abnormalities. They used Affymetrix HgU95A microarray analysis and found a significant decrease in the expression of 17 genes related to oligodendrocyte function. Eight of these genes encode structural components of myelin (CNP, MAG, MAL, myelin oligodendrocyte glycoprotein (MOG), MOBP, PMP22, PLLP, proteolipid protein 1 (PLP1)), five other genes encode enzymes involved in the synthesis of myelin constituents (ASPA, UGT8), or regulate myelin formation (ENPP2, EDG2, TF, KLK6). SOX10, which encodes a transcription factor regulating other myelination-related genes, was also down regulated. OLIG2, a transcription factor specific for oligodendrocytes and oligodendrocyte precursors and ERBB3, which is involved in oligodendrocyte differentiation were also down regulated together with a number of genes involved in axonal growth and synaptic function (Aston et al., 2005). Overall these gene expression changes suggest disturbed neuronal communication and signal transduction mechanisms.
A recent postmortem study examined myelin-related mRNA and protein expression in the white matter of the ventral PFC in MDD patients (Rajkowska et al., 2015). Quantitative RT-PCR revealed significantly reduced expression of PLP1 mRNA and increased expression of mRNA for CNPase, MOG and oligodendrocyte transcription factors 1 (Rajkowska et al., 2015). The expression of CNPase protein was also significantly decreased in MDD. These data suggests molecular mechanisms for the degeneration of cortical axons and dysfunctional maturation of oligodendrocytes in MDD (Rajkowska et al., 2015). In BD however, increased CNPase protein levels were reported in the white matter adjacent to the dorsolateral PFC (Brodmann area 9; Hercher et al., 2014).
Interestingly, increased mRNA levels of the oligodendroglial markers, Olig1 and Olig2, have been found also in the serum of BD patients (Ferensztajn-Rochowiak et al., 2016).
Numerous studies report on elevated inflammatory markers in a subgroup of patients with MDD and BD (for reviews see e.g., Rao et al., 2010; Rosenblat et al., 2014; Réus et al., 2015; Miller and Raison, 2016; Sayana et al., 2017). However, most of the studies report on cytokine abnormalities in the periphery (in the serum) of depressed patients. Direct evidences on elevated cytokines and Toll-like receptors in postmortem brain tissue of suicide victims have been reported recently by Pandey (2017). This study found significantly increased mRNA and protein expression of TNF-α, IL-1β, IL-6 and Toll-like receptors in the PFC of suicide victims (Pandey, 2017). Pantazatos et al. (2017) used next generation sequencing for whole-transcriptome profiling (RNA-seq) to identify genes, miRNA species, and molecular pathways that are altered in the dorsolateral PFC of MDD patients. They found altered immune-related gene expression in depression and suicide, and a markedly lower expression of genes associated with microglia and glial cell functions (Pantazatos et al., 2017).
Summary and Future Directions
There is ample evidence that glial abnormalities are present in the brains of depressed individuals. These glial changes affect all major glial cell types, astrocytes, microglia and oligodendrocytes and are detectable at multiple levels: at molecular, cellular and network level. Notably, we could not find any clinical studies on NG2-psoitive glia in the context of depressive disorders.
Here, we gathered the clinical observations and we did not consider the potential functional consequences, mainly because a number of recent excellent reviews discuss these issues. Astrocytes carry out a large number of vital cellular functions (e.g., Sofroniew and Vinters, 2010), their functional deficits can lead to various malfunctions, most prominently to disturbed glutamate and ion homeostasis, and to synaptic dysfunctions (see e.g., Rajkowska and Stockmeier, 2013; Jun et al., 2014; Verkhratsky and Parpura, 2016; Haroon et al., 2017; Sild et al., 2017; Wang et al., 2017). The main function of oligodendrocytes is to provide support and insulation to axons, thus, their dysfunction can lead to disrupted neuronal network connectivity and communication and consequently result in psychopathology (Menon, 2011; Edgar and Sibille, 2012). Plenty of evidences suggest neuroimmune etiology (Yirmiya et al., 2015; Miller and Raison, 2016; Haroon et al., 2017) or at least disturbed immune response regulation in a subgroup of depressed individuals (Mechawar and Savitz, 2016) and activated microglia is one player in this complex multifaceted process.
There are two key questions that should to be clarified in the future: (1) Are these glial changes represent the cause or the consequence of the disease? (2) Do these glial abnormalities relate to each other, or are they present in different subgroup of patients? Some argue that the different glial abnormalities are connected to each other. It has been proposed that the microglia mediated inflammatory processes can damage the oligodendrocytes and disrupt glutamate homeostasis by impairing astrocytic functions (Mechawar and Savitz, 2016; Haroon et al., 2017). Prospective clinical studies collecting blood samples for biomarker analysis and combining in vivo neuroimaging data with postmortem histopathological analysis could help to answer these important questions. The clinical studies should also investigate putative changes affecting NG2-expressing glial cells. Preclinical studies, targeting specific glial cell types in transgenic animals (Birey et al., 2015) can also provide valuable insights.
BC had the concept and wrote the parts on the cellular and molecular findings. SAN wrote the parts on the in vivo imaging data.
This work was financially supported by the following grant agencies: Hungarian Brain Research Program (KTIA_NAP_13-2-2014-0019 and 20017-1.2.1-NKP-2017-00002) and the EU Social Fund (EFOP-3.6.2-16-2017-00008, “The role of neuroinflammation in neurodegeneration: from molecules to clinics”). SAN was supported by the ÚNKP-17-3-III-PTE-315, the New National Excellence Program of the Ministry of Human Capacities. These grant agencies had no influence in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Abdallah, C. G., Hannestad, J., Mason, G. F., Holmes, S. E., DellaGioia, N., Sanacora, G., et al. (2017). Metabotropic glutamate receptor 5 and glutamate involvement in major depressive disorder: a multimodal imaging study. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 2, 449–456. doi: 10.1016/j.bpsc.2017.03.019
Abercrombie, H. C., Schaefer, S. M., Larson, C. L., Oakes, T. R., Lindgren, K. A., Holden, J. E., et al. (1998). Metabolic rate in the right amygdala predicts negative affect in depressed patients. Neuroreport 9, 3301–3307. doi: 10.1097/00001756-199810050-00028
Alexopoulos, G. S., Kiosses, D. N., Choi, S. J., Murphy, C. F., and Lim, K. O. (2002). Frontal white matter microstructure and treatment response of late-life depression: a preliminary study. Am. J. Psychiatry 159, 1929–1932. doi: 10.1176/appi.ajp.159.11.1929
Allaman, I., Fiumelli, H., Magistretti, P. J., and Martin, J. L. (2011). Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology 216, 75–84. doi: 10.1007/s00213-011-2190-y
Altshuler, L. L., Abulseoud, O. A., Foland-Ross, L., Bartzokis, G., Chang, S., Mintz, J., et al. (2010). Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder. Bipolar Disord. 12, 541–549. doi: 10.1111/j.1399-5618.2010.00838.x
Anderson, I. M. (2000). Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 58, 19–36. doi: 10.1016/s0165-0327(99)00092-0
Arnone, D., Mumuni, A. N., Jauhar, S., Condon, B., and Cavanagh, J. (2015). Indirect evidence of selective glial involvement in glutamate-based mechanisms of mood regulation in depression: meta-analysis of absolute prefrontal neuro-metabolic concentrations. Eur. Neuropsychopharmacol. 25, 1109–1117. doi: 10.1016/j.euroneuro.2015.04.016
Aston, C., Jiang, L., and Sokolov, B. P. (2005). Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol. Psychiatry 10, 309–322. doi: 10.1038/sj.mp.4001565
Bae, J. N., MacFall, J. R., Krishnan, K. R., Payne, M. E., Steffens, D. C., and Taylor, W. D. (2006). Dorsolateral prefrontal cortex and anterior cingulate cortex white matter alterations in late-life depression. Biol. Psychiatry 60, 1356–1363. doi: 10.1016/j.biopsych.2006.03.052
Baxter, L. R. Jr., Schwartz, J. M., Phelps, M. E., Mazziotta, J. C., Guze, B. H., Selin, C. E., et al. (1989). Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch. Gen. Psychiatry 46, 243–250. doi: 10.1001/archpsyc.1989.01810030049007
Bayer, T. A., Buslei, R., Havas, L., and Falkai, P. (1999). Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett. 271, 126–128. doi: 10.1016/s0304-3940(99)00545-5
Bernard, R., Kerman, I. A., Thompson, R. C., Jones, E. G., Bunney, W. E., Barchas, J. D., et al. (2011). Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol. Psychiatry 16, 634–646. doi: 10.1038/mp.2010.44
Bernstein, H. G., Meyer-Lotz, G., Dobrowolny, H., Bannier, J., Steiner, J., Walter, M., et al. (2015). Reduced density of glutamine synthetase immunoreactive astrocytes in different cortical areas in major depression but not in bipolar I disorder. Front. Cell. Neurosci. 9:273. doi: 10.3389/fncel.2015.00273
Bhagwagar, Z., Wylezinska, M., Jezzard, P., Evans, J., Ashworth, F., Sule, A., et al. (2007). Reduction in occipital cortex γ-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol. Psychiatry 61, 806–812. doi: 10.1016/j.biopsych.2006.08.048
Biber, K., Laurie, D. J., Berthele, A., Sommer, B., Tölle, T. R., Gebicke-Härter, P. J., et al. (1999). Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J. Neurochem. 72, 1671–1680. doi: 10.1046/j.1471-4159.1999.721671.x
Birey, F., Kloc, M., Chavali, M., Hussein, I., Wilson, M., Christoffel, D. J., et al. (2015). Genetic and stress-induced loss of NG2 glia triggers emergence of depressive-like behaviors through reduced secretion of FGF2. Neuron 88, 941–956. doi: 10.1016/j.neuron.2015.10.046
Bleys, D., Luyten, P., Soenens, B., and Claes, S. (2018). Gene-environment interactions between stress and 5-HTTLPR in depression: a meta-analytic update. J. Affect. Disord. 226, 339–345. doi: 10.1016/j.jad.2017.09.050
Brites, D., and Fernandes, A. (2015). Neuroinflammation and depression: microglia activation, extracellular microvesicles and microRNA dysregulation. Front. Cell. Neurosci. 9:476. doi: 10.3389/fncel.2015.00476
Bruno, S. D., Barker, G. J., Cercignani, M., Symms, M., and Ron, M. A. (2004). A study of bipolar disorder using magnetization transfer imaging and voxel-based morphometry. Brain 127, 2433–2440. doi: 10.1093/brain/awh274
Capuron, L., Pagnoni, G., Demetrashvili, M., Woolwine, B. J., Nemeroff, C. B., Berns, G. S., et al. (2005). Anterior cingulate activation and error processing during interferon-α treatment. Biol. Psychiatry 58, 190–196. doi: 10.1016/j.biopsych.2005.03.033
Cardoso de Almeida, J. R., and Phillips, M. L. (2013). Distinguishing between unipolar depression and bipolar depression: current and future clinical and neuroimaging perspectives. Biol. Psychiatry 73, 111–118. doi: 10.1016/j.biopsych.2012.06.010
Caverzasi, E., Pichiecchio, A., Poloni, G. U., Calligaro, A., Pasin, M., Palesi, F., et al. (2012). Magnetic resonance spectroscopy in the evaluation of treatment efficacy in unipolar major depressive disorder: a review of the literature. Funct. Neurol. 27, 13–22.
Chandley, M. J., Szebeni, K., Szebeni, A., Crawford, J., Stockmeier, C. A., Turecki, G., et al. (2013). Gene expression deficits in pontine locus coeruleus astrocytes in men with major depressive disorder. J. Psychiatry Neurosci. 38, 276–284. doi: 10.1503/jpn.120110
Chen, J. T., Collins, D. L., Atkins, H. L., Freedman, M. S., Arnold, D. L., and Canadian MS/BMT Study Group. (2008). Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann. Neurol. 63, 254–262. doi: 10.1002/ana.21302
Choi, J. L., Kao, P. F., Itriago, E., Zhan, Y., Kozubek, J. A., Hoss, A. G., et al. (2017). miR-149 and miR-29c as candidates for bipolar disorder biomarkers. Am. J. Med. Genet. B Neuropsychiatr. Genet. 174, 315–323. doi: 10.1002/ajmg.b.32518
Choudary, P. V., Molnar, M., Evans, S. J., Tomita, H., Li, J. Z., Vawter, M. P., et al. (2005). Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl. Acad. Sci. U S A 102, 15653–15658. doi: 10.1073/pnas.0507901102
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373, 746–758. doi: 10.1016/S0140-6736(09)60046-5
Cobb, J. A., O’Neill, K., Milner, J., Mahajan, G. J., Lawrence, T. J., May, W. L., et al. (2016). Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder. Neuroscience 316, 209–220. doi: 10.1016/j.neuroscience.2015.12.044
Cobb, J. A., Simpson, J., Mahajan, G. J., Overholser, J. C., Jurjus, G. J., Dieter, L., et al. (2013). Hippocampal volume and total cell numbers in major depressive disorder. J. Psychiatr. Res. 47, 299–306. doi: 10.1016/j.jpsychires.2012.10.020
Cotter, D., Hudson, L., and Landau, S. (2005). Evidence for orbitofrontal pathology in bipolar disorder and major depression, but not in schizophrenia. Bipolar Disord. 7, 358–369. doi: 10.1111/j.1399-5618.2005.00230.x
Cotter, D., Mackay, D., Chana, G., Beasley, C., Landau, S., and Everall, I. P. (2002). Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb. Cortex 12, 386–394. doi: 10.1093/cercor/12.4.386
Culverhouse, R. C., Saccone, N. L., Horton, A. C., Ma, Y., Anstey, K. J., Banaschewski, T., et al. (2018). Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. Mol. Psychiatry 23, 133–142. doi: 10.1038/mp.2017.44
Czéh, B., Müller-Keuker, J. I., Rygula, R., Abumaria, N., Hiemke, C., Domenici, E., et al. (2007). Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology 32, 1490–1503. doi: 10.1038/sj.npp.1301275
Czéh, B., Simon, M., Schmelting, B., Hiemke, C., and Fuchs, E. (2006). Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology 31, 1616–1626. doi: 10.1038/sj.npp.1300982
Dager, S. R., Friedman, S. D., Parow, A., Demopulos, C., Stoll, A. L., Lyoo, I. K., et al. (2004). Brain metabolic alterations in medication-free patients with bipolar disorder. Arch. Gen. Psychiatry 61, 450–458. doi: 10.1001/archpsyc.61.5.450
Damadzic, R., Bigelow, L. B., Krimer, L. S., Goldenson, D. A., Saunders, R. C., Kleinman, J. E., et al. (2001). A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: absence of significant astrocytosis. Brain Res. Bull. 55, 611–618. doi: 10.1016/s0361-9230(01)00529-9
de Diego-Adeliño, J., Pires, P., Gómez-Ansón, B., Serra-Blasco, M., Vives-Gilabert, Y., Puigdemont, D., et al. (2014). Microstructural white-matter abnormalities associated with treatment resistance, severity and duration of illness in major depression. Psychol. Med. 44, 1171–1182. doi: 10.1017/s003329171300158x
Deschwanden, A., Karolewicz, B., Feyissa, A. M., Treyer, V., Ametamey, S. M., Johayem, A., et al. (2011). Reduced metabotropic glutamate receptor 5 density in major depression determined by [11C]ABP688 PET and postmortem study. Am. J. Psychiatry 168, 727–734. doi: 10.1176/appi.ajp.2011.09111607
Di Benedetto, B., Malik, V. A., Begum, S., Jablonowski, L., Gómez-González, G. B., Neumann, I. D., et al. (2016). Fluoxetine requires the endfeet protein aquaporin-4 to enhance plasticity of astrocyte processes. Front. Cell. Neurosci. 10:8. doi: 10.3389/fncel.2016.00008
Drevets, W. C., Bogers, W., and Raichle, M. E. (2002a). Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur. Neuropsychopharmacol. 12, 527–544. doi: 10.1016/s0924-977x(02)00102-5
Drevets, W. C., Price, J. L., Bardgett, M. E., Reich, T., Todd, R. D., and Raichle, M. E. (2002b). Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol. Biochem. Behav. 71, 431–447. doi: 10.1016/s0091-3057(01)00687-6
Drevets, W. C., Price, J. L., Simpson, J. R. Jr., Todd, R. D., Reich, T., Vannier, M., et al. (1997). Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386, 824–827. doi: 10.1038/386824a0
Drysdale, A. T., Grosenick, L., Downar, J., Dunlop, K., Mansouri, F., Meng, Y., et al. (2017). Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat. Med. 23, 28–38. doi: 10.1038/nm.4246
Emsell, L., Leemans, A., Langan, C., Van Hecke, W., Barker, G. J., McCarthy, P., et al. (2013). Limbic and callosal white matter changes in euthymic bipolar I disorder: an advanced diffusion magnetic resonance imaging tractography study. Biol. Psychiatry 73, 194–201. doi: 10.1016/j.biopsych.2012.09.023
Ernst, J., Hock, A., Henning, A., Seifritz, E., Boeker, H., and Grimm, S. (2017). Increased pregenual anterior cingulate glucose and lactate concentrations in major depressive disorder. Mol. Psychiatry 22, 113–119. doi: 10.1038/mp.2016.73
Fatemi, S. H., Laurence, J. A., Araghi-Niknam, M., Stary, J. M., Schulz, S. C., Lee, S., et al. (2004). Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophr. Res. 69, 317–323. doi: 10.1016/j.schres.2003.08.014
Felger, J. C., Li, Z., Haroon, E., Woolwine, B. J., Jung, M. Y., Hu, X., et al. (2016). Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol. Psychiatry 21, 1358–1365. doi: 10.1038/mp.2015.168
Ferensztajn-Rochowiak, E., Tarnowski, M., Samochowiec, J., Michalak, M., Ratajczak, M. Z., and Rybakowski, J. K. (2016). Increased mRNA expression of peripheral glial cell markers in bipolar disorder: the effect of long-term lithium treatment. Eur. Neuropsychopharmacol. 26, 1516–1521. doi: 10.1016/j.euroneuro.2016.07.009
Ferrari, A. J., Charlson, F. J., Norman, R. E., Patten, S. B., Freedman, G., Murray, C. J., et al. (2013). Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 10:e1001547. doi: 10.1371/journal.pmed.1001547
Frye, M. A., Watzl, J., Banakar, S., O’Neill, J., Mintz, J., Davanzo, P., et al. (2007). Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacology 32, 2490–2499. doi: 10.1038/sj.npp.1301387
Gigante, A. D., Bond, D. J., Lafer, B., Lam, R. W., Young, L. T., and Yatham, L. N. (2012). Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord. 14, 478–487. doi: 10.1111/j.1399-5618.2012.01033.x
Gos, T., Schroeter, M. L., Lessel, W., Bernstein, H. G., Dobrowolny, H., Schiltz, K., et al. (2013). S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: a postmortem study. J. Psychiatr. Res. 47, 1694–1699. doi: 10.1016/j.jpsychires.2013.07.005
Grangeon, M. C., Seixas, C., Quarantini, L. C., Miranda-Scippa, A., Pompili, M., Steffens, D. C., et al. (2010). White matter hyperintensities and their association with suicidality in major affective disorders: a meta-analysis of magnetic resonance imaging studies. CNS Spectr. 15, 375–381. doi: 10.1017/s1092852900029242
Grieve, S. M., Korgaonkar, M. S., Koslow, S. H., Gordon, E., and Williams, L. M. (2013). Widespread reductions in gray matter volume in depression. Neuroimage Clin. 3, 332–339. doi: 10.1016/j.nicl.2013.08.016
Grimm, S., Beck, J., Schuepbach, D., Hell, D., Boesiger, P., Bermpohl, F., et al. (2008). Imbalance between left and right dorsolateral prefrontal cortex in major depression is linked to negative emotional judgment: an fMRI study in severe major depressive disorder. Biol. Psychiatry 63, 369–376. doi: 10.1016/j.biopsych.2007.05.033
Gunning-Dixon, F. M., Hoptman, M. J., Lim, K. O., Murphy, C. F., Klimstra, S., Latoussakis, V., et al. (2008). Macromolecular white matter abnormalities in geriatric depression: a magnetization transfer imaging study. Am. J. Geriatr. Psychiatry 16, 255–262. doi: 10.1097/jgp.0b013e3181602a66
Haarman, B. C. M., Burger, H., Doorduin, J., Renken, R. J., Sibeijn-Kuiper, A. J., Marsman, J. B., et al. (2016a). Volume, metabolites and neuroinflammation of the hippocampus in bipolar disorder—a combined magnetic resonance imaging and positron emission tomography study. Brain Behav. Immun. 56, 21–33. doi: 10.1016/j.bbi.2015.09.004
Haarman, B. C. M., Riemersma-Van der Lek, R. F., Burger, H., de Groot, J. C., Drexhage, H. A., Nolen, W. A., et al. (2016b). Diffusion tensor imaging in euthymic bipolar disorder—A tract-based spatial statistics study. J. Affect. Disord. 203, 281–291. doi: 10.1016/j.jad.2016.05.040
Haarman, B. C., Riemersma-Van der Lek, R. F., de Groot, J. C., Ruhé, H. G., Klein, H. C., Zandstra, T. E., et al. (2014). Neuroinflammation in bipolar disorder—A [11C]-(R)-PK11195 positron emission tomography study. Brain Behav. Immun. 40, 219–225. doi: 10.1016/j.bbi.2014.03.016
Hannestad, J., DellaGioia, N., Gallezot, J. D., Lim, K., Nabulsi, N., Esterlis, I., et al. (2013). The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [11C]PBR28 PET study. Brain Behav. Immun. 33, 131–138. doi: 10.1016/j.bbi.2013.06.010
Haroon, E., and Miller, A. H. (2017). Inflammation effects on brain glutamate in depression: mechanistic considerations and treatment implications. Curr. Top. Behav. Neurosci. 31, 173–198. doi: 10.1007/7854_2016_40
Haroon, E., Woolwine, B. J., Chen, X., Pace, T. W., Parekh, S., Spivey, J. R., et al. (2014). IFN-α-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology 39, 1777–1785. doi: 10.1038/npp.2014.25
Hayashi, Y., Nihonmatsu-Kikuchi, N., Yu, X., Ishimoto, K., Hisanaga, S. I., and Tatebayashi, Y. (2011). A novel, rapid, quantitative cell-counting method reveals oligodendroglial reduction in the frontopolar cortex in major depressive disorder. Mol. Psychiatry 16, 1155–1158. doi: 10.1038/mp.2011.84
Hercher, C., Chopra, V., and Beasley, C. L. (2014). Evidence for morphological alterations in prefrontal white matter glia in schizophrenia and bipolar disorder. J. Psychiatry Neurosci. 39, 376–385. doi: 10.1503/jpn.130277
Holmes, S. E., Hinz, R., Conen, S., Gregory, C. J., Matthews, J. C., Anton-Rodriguez, J. M., et al. (2018). Elevated translocator protein in anterior cingulate in major depression and a role for inflammation in suicidal thinking: a positron emission tomography study. Biol. Psychiatry 83, 61–69. doi: 10.1016/j.biopsych.2017.08.005
Honer, W. G., Falkai, P., Chen, C., Arango, V., Mann, J. J., and Dwork, A. J. (1999). Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness. Neuroscience 91, 1247–1255. doi: 10.1016/s0306-4522(98)00679-4
Ji, A., Godwin, D., Rutlin, J., Kandala, S., Shimony, J. S., and Mamah, D. (2017). Tract-based analysis of white matter integrity in psychotic and nonpsychotic bipolar disorder. J. Affect. Disord. 209, 124–134. doi: 10.1016/j.jad.2016.11.038
Jiang, J., Zhao, Y.-J., Hu, X.-Y., Du, M.-Y., Chen, Z.-Q., Wu, M., et al. (2017). Microstructural brain abnormalities in medication-free patients with major depressive disorder: a systematic review and meta-analysis of diffusion tensor imaging. J. Psychiatry Neurosci. 42, 150–163. doi: 10.1503/jpn.150341
John, C. S., Sypek, E. I., Carlezon, W. A., Cohen, B. M., Öngür, D., and Bechtholt, A. J. (2015). Blockade of the GLT-1 transporter in the central nucleus of the amygdala induces both anxiety and depressive-like symptoms. Neuropsychopharmacology 40, 1700–1708. doi: 10.1038/npp.2015.16
Kennedy, S. H., Evans, K. R., Kruger, S., Mayberg, H. S., Meyer, J. H., McCann, S., et al. (2001). Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am. J. Psychiatry 158, 899–905. doi: 10.1176/appi.ajp.158.987.899
Khundakar, A. A., Morris, C. M., Oakley, A. E., and Thomas, A. J. (2011). Cellular pathology within the anterior cingulate cortex of patients with late-life depression: a morphometric study. Psychiatry Res. 194, 184–189. doi: 10.1016/j.pscychresns.2011.04.008
Kim, S., and Webster, M. J. (2010). Correlation analysis between genome-wide expression profiles and cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol. Psychiatry 15, 326–336. doi: 10.1038/mp.2008.99
Kodama, M., Fujioka, T., and Duman, R. S. (2004). Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol. Psychiatry 56, 570–580. doi: 10.1016/j.biopsych.2004.07.008
Konopaske, G. T., Dorph-Petersen, K. A., Pierri, J. N., Wu, Q., Sampson, A. R., and Lewis, D. A. (2007). Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology 32, 1216–1223. doi: 10.1038/sj.npp.1301233
Konopaske, G. T., Dorph-Petersen, K. A., Sweet, R. A., Pierri, J. N., Zhang, W., Sampson, A. R., et al. (2008). Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol. Psychiatry 63, 759–765. doi: 10.1016/j.biopsych.2007.08.018
Kumar, A., Gupta, R. C., Albert Thomas, M., Alger, J., Wyckoff, N., and Hwang, S. (2004). Biophysical changes in normal-appearing white matter and subcortical nuclei in late-life major depression detected using magnetization transfer. Psychiatry Res. 130, 131–140. doi: 10.1016/j.pscychresns.2003.12.002
Lee, K. M., Chiu, K. B., Didier, P. J., Baker, K. C., and MacLean, A. G. (2015). Naltrexone treatment reverses astrocyte atrophy and immune dysfunction in self-harming macaques. Brain Behav. Immun. 50, 288–297. doi: 10.1016/j.bbi.2015.07.017
Lu, L. H., Zhou, X. J., Fitzgerald, J., Keedy, S. K., Reilly, J. L., Passarotti, A. M., et al. (2012). Microstructural abnormalities of white matter differentiate pediatric and adult-onset bipolar disorder. Bipolar Disord. 14, 597–606. doi: 10.1111/j.1399-5618.2012.01045.x
Lu, L. H., Zhou, X. J., Keedy, S. K., Reilly, J. L., and Sweeney, J. A. (2011). White matter microstructure in untreated first episode bipolar disorder with psychosis: comparison with schizophrenia. Bipolar Disord. 13, 604–613. doi: 10.1111/j.1399-5618.2011.00958.x
Luykx, J. J., Laban, K. G., van den Heuvel, M. P., Boks, M. P., Mandl, R. C., Kahn, R. S., et al. (2012). Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of 1H-MRS findings. Neurosci. Biobehav. Rev. 36, 198–205. doi: 10.1016/j.neubiorev.2011.05.014
Ma, N., Li, L., Shu, N., Liu, J., Gong, G., He, Z., et al. (2007). White matter abnormalities in first-episode, treatment-naive young adults with major depressive disorder. Am. J. Psychiatry 164, 823–826. doi: 10.1176/ajp.2007.164.5.823
Mächler, P., Wyss, M. T., Elsayed, M., Stobart, J., Gutierrez, R., von Faber-Castell, A., et al. (2016). In vivo evidence for a lactate gradient from astrocytes to neurons. Cell Metab. 23, 94–102. doi: 10.1016/j.cmet.2015.10.010
Madsen, T. M., Yeh, D. D., Valentine, G. W., and Duman, R. S. (2005). Electroconvulsive seizure treatment increases cell proliferation in rat frontal cortex. Neuropsychopharmacology 30, 27–34. doi: 10.1038/sj.npp.1300565
Magistretti, P. J., and Pellerin, L. (1999). Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos. Trans. R. Soc. Lond B Biol. Sci. 354, 1155–1163. doi: 10.1098/rstb.1999.0471
Manji, H., Kato, T., Di Prospero, N. A., Ness, S., Beal, M. F., Krams, M., et al. (2012). Impaired mitochondrial function in psychiatric disorders. Nat. Rev. Neurosci. 13, 293–307. doi: 10.1038/nrn3229
Martinot, J. L., Hardy, P., Feline, A., Huret, J. D., Mazoyer, B., Attar-Levy, D., et al. (1990). Left prefrontal glucose hypometabolism in the depressed state: a confirmation. Am. J. Psychiatry 147, 1313–1317. doi: 10.1176/ajp.147.10.1313
Matsuoka, K., Yasuno, F., Kishimoto, T., Yamamoto, A., Kiuchi, K., Kosaka, J., et al. (2017). Microstructural differences in the corpus callosum in patients with bipolar disorder and major depressive disorder. J. Clin. Psychiatry 78, 99–104. doi: 10.4088/jcp.15m09851
Medina, A., Burke, S., Thompson, R. C., Bunney, W. Jr., Myers, R. M., Schatzberg, A., et al. (2013). Glutamate transporters: a key piece in the glutamate puzzle of major depressive disorder. J. Psychiatr. Res. 47, 1150–1156. doi: 10.1016/j.jpsychires.2013.04.007
Medina, A., Watson, S. J., Bunney, W. Jr., Myers, R. M., Schatzberg, A., Barchas, J., et al. (2016). Evidence for alterations of the glial syncytial function in major depressive disorder. J. Psychiatr. Res. 72, 15–21. doi: 10.1016/j.jpsychires.2015.10.010
Meyer, J. H., Ginovart, N., Boovariwala, A., Sagrati, S., Hussey, D., Garcia, A., et al. (2006). Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry 63, 1209–1216. doi: 10.1001/archpsyc.63.11.1209
Michael, N., Erfurth, A., Ohrmann, P., Arolt, V., Heindel, W., and Pfleiderer, B. (2003). Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychol. Med. 33, 1277–1284. doi: 10.1017/s0033291703007931
Miguel-Hidalgo, J. J., Baucom, C., Dilley, G., Overholser, J. C., Meltzer, H. Y., Stockmeier, C. A., et al. (2000). Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol. Psychiatry 48, 861–873. doi: 10.1016/s0006-3223(00)00999-9
Miguel-Hidalgo, J. J., Waltzer, R., Whittom, A. A., Austin, M. C., Rajkowska, G., and Stockmeier, C. A. (2010). Glial and glutamatergic markers in depression, alcoholism, and their comorbidity. J. Affect. Disord. 127, 230–240. doi: 10.1016/j.jad.2010.06.003
Millan, M. J. (2006). Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 110, 135–370. doi: 10.1016/j.pharmthera.2005.11.006
Moffett, J. R., Ross, B., Arun, P., Madhavarao, C. N., and Namboodiri, A. M. (2007). N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog. Neurobiol. 81, 89–131. doi: 10.1016/j.pneurobio.2006.12.003
Montgomery, S. A., Baldwin, D. S., and Riley, A. (2002). Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J. Affect. Disord. 69, 119–140. doi: 10.1016/s0165-0327(01)00313-5
Mulders, P. C., van Eijndhoven, P. F., Schene, A. H., Beckmann, C. F., and Tendolkar, I. (2015). Resting-state functional connectivity in major depressive disorder: a review. Neurosci. Biobehav. Rev. 56, 330–344. doi: 10.1016/j.neubiorev.2015.07.014
Murck, H., Schubert, M. I., Schmid, D., Schussler, P., Steiger, A., and Auer, D. P. (2009). The glutamatergic system and its relation to the clinical effect of therapeutic-sleep deprivation in depression—an MR spectroscopy study. J. Psychiatr. Res. 43, 175–180. doi: 10.1016/j.jpsychires.2008.04.009
Nagy, C., Torres-Platas, S. G., Mechawar, N., and Turecki, G. (2017). Repression of astrocytic connexins in cortical and subcortical brain regions and prefrontal enrichment of H3K9me3 in depression and suicide. Int. J. Neuropsychopharmacol. 20, 50–57. doi: 10.1093/ijnp/pyw071
Nikolaus, S., Antke, C., and Müller, H. W. (2009). In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Behav. Brain Res. 204, 32–66. doi: 10.1016/j.bbr.2009.06.009
Öngür, D., Jensen, J. E., Prescot, A. P., Stork, C., Lundy, M., Cohen, B. M., et al. (2008). Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol. Psychiatry 64, 718–726. doi: 10.1016/j.biopsych.2008.05.014
Öngür, D., Pohlman, J., Dow, A. L., Eisch, A. J., Edwin, F., Heckers, S., et al. (2007). Electroconvulsive seizures stimulate glial proliferation and reduce expression of Sprouty2 within the prefrontal cortex of rats. Biol. Psychiatry 62, 505–512. doi: 10.1016/j.biopsych.2006.11.014
Orre, K., Wennstrom, M., and Tingström, A. (2009). Chronic lithium treatment decreases NG2 cell proliferation in rat dentate hilus, amygdala and corpus callosum. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 503–510. doi: 10.1016/j.pnpbp.2009.01.015
Osoba, A., Hanggi, J., Li, M., Horn, D. I., Metzger, C., Eckert, U., et al. (2013). Disease severity is correlated to tract specific changes of fractional anisotropy in MD and CM thalamus—a DTI study in major depressive disorder. J. Affect. Disord. 149, 116–128. doi: 10.1016/j.jad.2012.12.026
Pantazatos, S. P., Huang, Y. Y., Rosoklija, G. B., Dwork, A. J., Arango, V., and Mann, J. J. (2017). Whole-transcriptome brain expression and exon-usage profiling in major depression and suicide: evidence for altered glial, endothelial and ATPase activity. Mol. Psychiatry 22, 760–773. doi: 10.1038/mp.2016.130
Pellerin, L., Bouzier-Sore, A. K., Aubert, A., Serres, S., Merle, M., Costalat, R., et al. (2007). Activity-dependent regulation of energy metabolism by astrocytes: an update. Glia 55, 1251–1262. doi: 10.1002/glia.20528
Pfleiderer, B., Michael, N., Erfurth, A., Ohrmann, P., Hohmann, U., Wolgast, M., et al. (2003). Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res. 122, 185–192. doi: 10.1016/s0925-4927(03)00003-9
Pompili, M., Innamorati, M., Mann, J. J., Oquendo, M. A., Lester, D., Del Casale, A., et al. (2008). Periventricular white matter hyperintensities as predictors of suicide attempts in bipolar disorders and unipolar depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1501–1507. doi: 10.1016/j.pnpbp.2008.05.009
Potokar, M., Stenovec, M., Gabrijel, M., Li, L., Kreft, M., Grilc, S., et al. (2010). Intermediate filaments attenuate stimulation-dependent mobility of endosomes/lysosomes in astrocytes. Glia 58, 1208–1219. doi: 10.1002/glia.21000
Raison, C. L., Borisov, A. S., Majer, M., Drake, D. F., Pagnoni, G., Woolwine, B. J., et al. (2009). Activation of central nervous system inflammatory pathways by interferon-α: relationship to monoamines and depression. Biol. Psychiatry 65, 296–303. doi: 10.1016/j.biopsych.2008.08.010
Rajkowska, G., Clarke, G., Mahajan, G., Licht, C. M., van de Werd, H. J., Yuan, P., et al. (2016). Differential effect of lithium on cell number in the hippocampus and prefrontal cortex in adult mice: a stereological study. Bipolar Disord. 18, 41–51. doi: 10.1111/bdi.12364
Rajkowska, G., Halaris, A., and Selemon, L. D. (2001). Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol. Psychiatry 49, 741–752. doi: 10.1016/s0006-3223(01)01080-0
Rajkowska, G., Hughes, J., Stockmeier, C. A., Javier Miguel-Hidalgo, J., and Maciag, D. (2013). Coverage of blood vessels by astrocytic endfeet is reduced in major depressive disorder. Biol. Psychiatry 73, 613–621. doi: 10.1016/j.biopsych.2012.09.024
Rajkowska, G., Mahajan, G., Maciag, D., Sathyanesan, M., Iyo, A. H., Moulana, M., et al. (2015). Oligodendrocyte morphometry and expression of myelin—Related mRNA in ventral prefrontal white matter in major depressive disorder. J. Psychiatr. Res. 65, 53–62. doi: 10.1016/j.jpsychires.2015.04.010
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., et al. (1999). Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry 45, 1085–1098. doi: 10.1016/s0006-3223(99)00041-4
Rajkowska, G., and Stockmeier, C. A. (2013). Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr. Drug Targets 14, 1225–1236. doi: 10.2174/13894501113149990156
Rao, J. S., Harry, G. J., Rapoport, S. I., and Kim, H. W. (2010). Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry 15, 384–392. doi: 10.1038/mp.2009.47
Réus, G. Z., Fries, G. R., Stertz, L., Badawy, M., Passos, I. C., Barichello, T., et al. (2015). The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 300, 141–154. doi: 10.1016/j.neuroscience.2015.05.018
Rosenblat, J. D., Cha, D. S., Mansur, R. B., and McIntyre, R. S. (2014). Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 53, 23–34. doi: 10.1016/j.pnpbp.2014.01.013
Rosenzweig, I., Vukadinovic, Z., Turner, A. J., and Catani, M. (2012). Neuroconnectivity and valproic acid: the myelin hypothesis. Neurosci. Biobehav. Rev. 36, 1848–1856. doi: 10.1016/j.neubiorev.2012.05.006
Rubinow, M. J., Mahajan, G., May, W., Overholser, J. C., Jurjus, G. J., Dieter, L., et al. (2016). Basolateral amygdala volume and cell numbers in major depressive disorder: a postmortem stereological study. Brain Struct. Funct. 221, 171–184. doi: 10.1007/s00429-014-0900-z
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. J. Psychiatr. Res. 163, 1905–1917. doi: 10.1176/appi.ajp.163.11.1905
Sanacora, G., Gueorguieva, R., Epperson, C. N., Wu, Y. T., Appel, M., Rothman, D. L., et al. (2004). Subtype-specific alterations of γ-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry 61, 705–713. doi: 10.1001/archpsyc.61.7.705
Sayana, P., Colpo, G. D., Simões, L. R., Giridharan, V. V., Teixeira, A. L., Quevedo, J., et al. (2017). A systematic review of evidence for the role of inflammatory biomarkers in bipolar patients. J. Psychiatr. Res. 92, 160–182. doi: 10.1016/j.jpsychires.2017.03.018
Schnieder, T. P., Trencevska, I., Rosoklija, G., Stankov, A., Mann, J. J., Smiley, J., et al. (2014). Microglia of prefrontal white matter in suicide. J. Neuropathol. Exp. Neurol. 73, 880–890. doi: 10.1097/NEN.0000000000000107
Setiawan, E., Wilson, A. A., Mizrahi, R., Rusjan, P. M., Miler, L., Rajkowska, G., et al. (2015). Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 72, 268–275. doi: 10.1001/jamapsychiatry.2014.2427
Si, X., Miguel-Hidalgo, J. J., O’Dwyer, G., Stockmeier, C. A., and Rajkowska, G. (2004). Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology 29, 2088–2096. doi: 10.1038/sj.npp.1300525
Sild, M., Ruthazer, E. S., and Booij, L. (2017). Major depressive disorder and anxiety disorders from the glial perspective: etiological mechanisms, intervention and monitoring. Neurosci. Biobehav. Rev. 83, 474–488. doi: 10.1016/j.neubiorev.2017.09.014
Smagula, S. F., and Aizenstein, H. J. (2016). Brain structural connectivity in late-life major depressive disorder. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 1, 271–277. doi: 10.1016/j.bpsc.2015.11.005
Soeiro-de-Souza, M. G., Henning, A., Machado-Vieira, R., Moreno, R. A., Pastorello, B. F., da Costa Leite, C., et al. (2015). Anterior cingulate Glutamate-Glutamine cycle metabolites are altered in euthymic bipolar I disorder. Eur. Neuropsychopharmacol. 25, 2221–2229. doi: 10.1016/j.euroneuro.2015.09.020
Spilt, A., Goekoop, R., Westendorp, R. G., Blauw, G. J., de Craen, A. J., and van Buchem, M. A. (2006). Not all age-related white matter hyperintensities are the same: a magnetization transfer imaging study. Am. J. Neuroradiol. 27, 1964–1968.
Sprooten, E., Barrett, J., McKay, D. R., Knowles, E. E., Mathias, S. R., Winkler, A. M., et al. (2016). A comprehensive tractography study of patients with bipolar disorder and their unaffected siblings. Hum. Brain Mapp. 37, 3474–3485. doi: 10.1002/hbm.23253
Sprooten, E., Brumbaugh, M. S., Knowles, E. E., McKay, D. R., Lewis, J., Barrett, J., et al. (2013). Reduced white matter integrity in sibling pairs discordant for bipolar disorder. Am. J. Psychiatry 170, 1317–1325. doi: 10.1176/appi.ajp.2013.12111462
Stankoff, B., Freeman, L., Aigrot, M. S., Chardain, A., Dollé, F., Williams, A., et al. (2011). Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-11C]-2–(4′-methylaminophenyl)- 6-hydroxybenzothiazole. Ann. Neurol. 69, 673–680. doi: 10.1002/ana.22320
Stankoff, B., Wang, Y., Bottlaender, M., Aigrot, M. S., Dolle, F., Wu, C., et al. (2006). Imaging of CNS myelin by positron-emission tomography. Proc. Natl. Acad. Sci. U S A 103, 9304–9309. doi: 10.1073/pnas.0600769103
Steiner, J., Bielau, H., Brisch, R., Danos, P., Ullrich, O., Mawrin, C., et al. (2008). Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res. 42, 151–157. doi: 10.1016/j.jpsychires.2006.10.013
Steiner, J., Walter, M., Gos, T., Guillemin, G. J., Bernstein, H. G., Sarnyai, Z., et al. (2011). Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J. Neuroinflammation 8:94. doi: 10.1186/1742-2094-8-94
Stockmeier, C. A., Mahajan, G. J., Konick, L. C., Overholser, J. C., Jurjus, G. J., Meltzer, H. Y., et al. (2004). Cellular changes in the postmortem hippocampus in major depression. Biol. Psychiatry 56, 640–650. doi: 10.1016/j.biopsych.2004.08.022
Su, L., Cai, Y., Xu, Y., Dutt, A., Shi, S., and Bramon, E. (2014). Cerebral metabolism in major depressive disorder: a voxel-based meta-analysis of positron emission tomography studies. BMC Psychiatry 14:321. doi: 10.1186/s12888-014-0321-9
Taylor, W. D., MacFall, J. R., Payne, M. E., McQuoid, D. R., Provenzale, J. M., Steffens, D. C., et al. (2004). Late-life depression and microstructural abnormalities in dorsolateral prefrontal cortex white matter. Am. J. Psychiatry 161, 1293–1296. doi: 10.1176/appi.ajp.161.7.1293
Taylor, M., Murphy, S. E., Selvaraj, S., Wylezinkska, M., Jezzard, P., Cowen, P. J., et al. (2008). Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy. J. Psychopharmacol. 22, 473–476. doi: 10.1177/0269881107081510
Tiwari, A. D., Wu, C., Zhu, J., Zhang, S., Zhu, J., Wang, W. R., et al. (2016). Design, synthesis and evaluation of fluorinated radioligands for myelin imaging. J. Med. Chem. 59, 3705–3718. doi: 10.1021/acs.jmedchem.5b01858
Tkachev, D., Mimmack, M. L., Ryan, M. M., Wayland, M., Freeman, T., Jones, P. B., et al. (2003). Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362, 798–805. doi: 10.1016/s0140-6736(03)14297-3
Torres-Platas, S. G., Cruceanu, C., Chen, G. G., Turecki, G., and Mechawar, N. (2014). Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain Behav. Immun. 42, 50–59. doi: 10.1016/j.bbi.2014.05.007
Torres-Platas, S. G., Hercher, C., Davoli, M. A., Maussion, G., Labonté, B., Turecki, G., et al. (2011). Astrocytic hypertrophy in anterior cingulate white matter of depressed suicides. Neuropsychopharmacology 36, 2650–2658. doi: 10.1038/npp.2011.154
Torres-Platas, S. G., Nagy, C., Wakid, M., Turecki, G., and Mechawar, N. (2016). Glial fibrillary acidic protein is differentially expressed across cortical and subcortical regions in healthy brains and downregulated in the thalamus and caudate nucleus of depressed suicides. Mol. Psychiatry 21, 509–515. doi: 10.1038/mp.2015.65
Tully, P. J., Debette, S., Mazoyer, B., and Tzourio, C. (2017). White matter lesions are associated with specific depressive symptom trajectories among incident depression and dementia populations: three-city dijon MRI study. Am. J. Geriatr. Psychiatry 25, 1311–1321. doi: 10.1016/j.jagp.2017.06.003
Uranova, N., Orlovskaya, D., Vikhreva, O., Zimina, I., Kolomeets, N., Vostrikov, V., et al. (2001). Electron microscopy of oligodendroglia in severe mental illness. Brain Res. Bull. 55, 597–610. doi: 10.1016/s0361-9230(01)00528-7
Uranova, N. A., Vostrikov, V. M., Orlovskaya, D. D., and Rachmanova, V. I. (2004). Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 67, 269–275. doi: 10.1016/s0920-9964(03)00181-6
van Tol, M. J., van der Wee, N. J., van den Heuvel, O. A., Nielen, M. M., Demenescu, L. R., Aleman, A., et al. (2010). Regional brain volume in depression and anxiety disorders. Arch. Gen. Psychiatry 67, 1002–1011. doi: 10.1001/archgenpsychiatry.2010.121
Vostrikov, V. M., Uranova, N. A., and Orlovskaya, D. D. (2007). Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr. Res. 94, 273–280. doi: 10.1016/j.schres.2007.04.014
Wang, Y., Jia, Y., Xu, G., Ling, X., Liu, S., and Huang, L. (2012). Frontal white matter biochemical abnormalities in first-episode, treatment-naive patients with major depressive disorder: a proton magnetic resonance spectroscopy study. J. Affect. Disord. 136, 620–626. doi: 10.1016/j.jad.2011.10.020
Wang, Y., Wu, C., Caprariello, A. V., Somoza, E., Zhu, W., Wang, C., et al. (2009). In vivo quantification of myelin changes in the vertebrate nervous system. J. Neurosci. 29, 14663–14669. doi: 10.1523/JNEUROSCI.4082-08.2009
Webster, M. J., O’Grady, J., Kleinman, J. E., and Weickert, C. S. (2005). Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 133, 453–461. doi: 10.1016/j.neuroscience.2005.02.037
Wennström, M., Hellsten, J., Ekstrand, J., Lindgren, H., and Tingström, A. (2006). Corticosterone-induced inhibition of gliogenesis in rat hippocampus is counteracted by electroconvulsive seizures. Biol. Psychiatry 59, 178–186. doi: 10.1016/j.biopsych.2005.08.032
Wennström, M., Hellsten, J., and Tingstræm, A. (2004). Electroconvulsive seizures induce proliferation of NG2-expressing glial cells in adult rat amygdala. Biol. Psychiatry 55, 464–471. doi: 10.1016/j.biopsych.2003.11.011
Williams, M. R., Sharma, P., Fung, K. L., Pearce, R. K., Hirsch, S. R., and Maier, M. (2015). Axonal myelin increase in the callosal genu in depression but not schizophrenia. Psychol. Med. 45, 2145–2155. doi: 10.1017/s0033291715000136
Wu, C., Wang, C., Popescu, D. C., Zhu, W., Somoza, E. A., Zhu, J., et al. (2010). A novel PET marker for in vivo quantification of myelination. Bioorg. Med. Chem. 18, 8592–8599. doi: 10.1016/j.bmc.2010.10.018
Yamada, S., Takahashi, S., Ukai, S., Tsuji, T., Iwatani, J., Tsuda, K., et al. (2015). Microstructural abnormalities in anterior callosal fibers and their relationship with cognitive function in major depressive disorder and bipolar disorder: a tract-specific analysis study. J. Affect. Disord. 174, 542–548. doi: 10.1016/j.jad.2014.12.022
Yildiz-Yesiloglu, A., and Ankerst, D. P. (2006). Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 969–995. doi: 10.1016/j.pnpbp.2006.03.012
Zhang, J., Narr, K. L., Woods, R. P., Phillips, O. R., Alger, J. R., and Espinoza, R. T. (2013). Glutamate normalization with ECT treatment response in major depression. Mol. Psychiatry 18, 268–270. doi: 10.1038/mp.2012.46
Zhao, M., Chen, L., Yang, J., Han, D., Fang, D., Qiu, X., et al. (2018). BDNF Val66Met polymorphism, life stress and depression: a meta-analysis of gene-environment interaction. J. Affect. Disord. 227, 226–235. doi: 10.1016/j.jad.2017.10.024
Zhao, J., Verwer, R. W., van Wamelen, D. J., Qi, X. R., Gao, S. F., Lucassen, P. J., et al. (2016). Prefrontal changes in the glutamate-glutamine cycle and neuronal/glial glutamate transporters in depression with and without suicide. J. Psychiatr. Res. 82, 8–15. doi: 10.1016/j.jpsychires.2016.06.017
Zhong, S., Wang, Y., Zhao, G., Xiang, Q., Ling, X., Liu, S., et al. (2014). Similarities of biochemical abnormalities between major depressive disorder and bipolar depression: a proton magnetic resonance spectroscopy study. J. Affect. Disord. 168, 380–386. doi: 10.1016/j.jad.2014.07.024
Keywords: astrocyte, depression, magnetic resonance imaging, microglia, oligodendrocyte, oligodendroglia, PET
Citation: Czéh B and Nagy SA (2018) Clinical Findings Documenting Cellular and Molecular Abnormalities of Glia in Depressive Disorders. Front. Mol. Neurosci. 11:56. doi: 10.3389/fnmol.2018.00056
Received: 11 December 2017; Accepted: 09 February 2018;
Published: 27 February 2018.
Edited by:Alexej Verkhratsky, University of Manchester, United Kingdom
Reviewed by:Vladimir Parpura, University of Alabama at Birmingham, United States
Barbara Di Benedetto, University of Regensburg, Germany
Copyright © 2018 Czéh and Nagy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Boldizsár Czéh, email@example.com